The use of bone grafts and substitutes reduces the need to harvest autograft bones from patients, which in turn reduces postoperative pain and healing time. Increased use of bone graft substitutes facilitates minimally invasive surgeries and short surgical procedures.‐ ‐Although these procedures were initially used for spinal fusion and rectification of deformities, the adoption of these procedures has increased for various applications including extremity reconstruction and treatment of fractures.
According to a report published by Allied Market Research, Global Bone Grafts and Substitutes Market was valued at $2,443 million in 2015, and is expected to reach $3,397 million by 2022, registering a CAGR of 4.1% during the forecast period 2016‐2022.
Increase in incidence of bone & joint disorders, technological advancements in medical field, development of biocompatible synthetic bone grafts, increase in demand for dental bone grafts drive the bone grafts and substitutes market. However, high cost of surgeries and ethical issues related to bone grafting procedures hamper the market growth. Conversely, increase in focus of key players towards R&D activities in bone grafts and its substitutes and upsurge in demand for orthopedic procedures among geriatric population are expected to provide lucrative opportunities for the market players in the future.
Get the PDF brochure of this market study: https://www.alliedmarketresearch.com/request-sample/1774
According to AMR analysis, bone graft substitutes segment accounted for more than half of the overall market in 2015, and is expected to dominate the market during the forecast period. This is attributed to the increase in prevalence of bone and joint disorders. In addition, these bone graft substitutes are used in varied applications such as bone replacement, posttraumatic skeletal conditions, and other bone-related problems. Moreover, advancements in bone graft materials and development of innovative products have fueled the market growth.
Top Impacting Factors:
- Increasing incidence of musculoskeletal conditions
- Technological advancements in medical devices leading to shift from autograft to allograft procedures
- Development of biocompatible synthetic bone grafts
- Obesity and diabetes to increase the risk of degenerative joint diseases
- High cost of surgeries
- Ethical issues related with bone grafting procedures
The major players operating in this market include Medtronic plc, Stryker Corporation, DePuy Synthes, Integra Lifesciences Holdings Corporation, Wright Medical Group N.V., Zimmer Biomet Holdings, Inc., Xtant Medical Holdings, Inc. (Bacterin), Arthrex, Inc., Baxter International Inc., and Musculoskeletal Transplant Foundation (MTF). The other players (profiles not included in the report) in the value chain include NovaBone Products, LLC, BonAlive Biomaterials Ltd., Sigma Graft Biomaterials, Pioneer Surgical Technology Inc., RTI Biologics, Inc., Orthofix International N.V., Citagenix Inc., Heraeus Medical GmbH, Graftys SA, and NuVasive, Inc.